Novel approaches in the treatment of myositis and myopathies

Research output: Contribution to journalReview articlepeer-review

Abstract

The inflammatory myopathies are a heterogeneous group of disorders characterized by muscle weakness and inflammation. Although no standard therapeutic guidelines exist, traditional treatment has included corticosteroids and a variety of second-line immunosuppressants. As treatment of refractory disease has been difficult, newer agents and approaches have been used with varying response. The advent of standardized treatment response criteria by the International Myositis Assessment and Clinical Studies (IMACS) group has helped investigators to evaluate and compare clinical trial outcomes in a more rigorous fashion. The use of intravenous immunoglobulin (IVIG), rituximab, biologic agents including tumor necrosis factor (TNF) inhibitors, stem-cell transplantation, gene therapy, and vascular occlusion resistance training are reviewed here. As our understanding of disease pathogenesis at the immunologic, genetic, and molecular level expands, the discovery of novel therapeutic targets hold promise for the successful treatment of these conditions.

Original languageEnglish (US)
Pages (from-to)369-377
Number of pages9
JournalTherapeutic Advances in Musculoskeletal Disease
Volume4
Issue number5
DOIs
StatePublished - Oct 2012

Keywords

  • IVIG
  • gene therapy
  • idiopathic inflammatory myopathies
  • novel approaches
  • rituximab
  • stem-cell transplantation

ASJC Scopus subject areas

  • Rheumatology
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Novel approaches in the treatment of myositis and myopathies'. Together they form a unique fingerprint.

Cite this